Keating Financial Advisory Services’s Novo Nordisk NVO Stock Holding History

Keating Financial Advisory Services’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$176K	Sell	3,661 -436	-11%	-$18.7K	0.02%	373
2026 Q1	$151K	Buy	4,097 +1,219	+42%	+$57.8K	0.02%	379
2025 Q4	$146K	Buy	+2,878	New	+$147K	0.02%	424

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Keating Financial Advisory Services's NVO Position: Q2 2026 in Review

Keating Financial Advisory Services reduced its Novo Nordisk (NVO) stake by 11% in Q2 2026, selling an estimated $18.7K and leaving 3,661 shares worth $176K. The position accounts for 0.02% of the portfolio, ranked #373.

Keating Financial Advisory Services first reported a position in NVO in Q4 2025 and has held it in 3 quarters since. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Keating Financial Advisory Services held 3,661 shares of Novo Nordisk worth $176K as of Q2 2026.
Keating Financial Advisory Services sold 436 Novo Nordisk shares in Q2 2026, an estimated $18.7K.
Novo Nordisk made up 0.02% of Keating Financial Advisory Services's portfolio in Q2 2026, its #373 holding.
Keating Financial Advisory Services first reported a position in Novo Nordisk in Q4 2025 and has held it in 3 quarters since.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.